PRA Health's data unit Symphony Health pens Close-Up International deal

PRA Health Sciences
Symphony Health penned a deal with Close-Up International aimed at boosting its global data services. (PRA Health Sciences)

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.

PRA’s Symphony, the company’s data solutions division, is working with the Latin American-based provider of medical prescription and sales audits to “exclusively distribute one another’s retail and non-retail data in their respective geographies,” according to a statement from the pair.

“The agreement with Close-Up represents a significant milestone in Symphony Health’s commitment to expanding our services internationally,” said Doug Fulling, president of Symphony Health.

“The presence across up to a dozen geographies adds a critical component to Symphony’s offerings that will build and strengthen relationships for both organizations in the United States and Latin America. The data solutions and insights available through Symphony and Close-Up International will drive future drug development and commercialization strategies.”

At the start of the month, and nearly three years after it first teamed up with Takeda Pharmaceutical, PRA bought out its joint venture with the Japanese pharma.

Previously known as the Takeda PRA Development Center, the unit was renamed PRA Health Sciences K.K. and is now operating in Japan as a subsidiary of PRA.

“As we build this alliance, we are focused on bringing greater value to our clients who operate in both of our geographies, helping them to achieve their business objectives while working with the leading providers of data solutions and insights,” added Norberto Bonaparte, CEO and founder of Close-Up.

“We are committed to bringing innovative solutions to the market as part of this alliance that will benefit our clients’ growth strategies.”

Suggested Articles

Peter Doshi has penned an opinion piece in the BMJ pointing out that current COVID-19 vaccine tests are not set up to save lives.

IQVIA is still steering around COVID-19 roadblocks with its R&D business still posting a loss, but other segments are recovering.

After snapping up contract research organization Covance for $6.5 billion five years ago, LabCorp is now looking to change the makeup of its drug dev